HSR Act Waiting Period Terminated for United Therapeutics' Acquisition of SteadyMed Ltd.
As previously announced on
The transaction is expected to close in the second half of 2018. Under Israeli law, the closing may not occur until at least thirty days have passed since the
Additional Information and Where to Find It
In connection with the proposed merger,
Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the timing of the consummation of the business combination transaction between
TREVYENT and PATCHPUMP are registered trademarks of
United Therapeutics: James Edgemond, Phone: (301) 608-9292, Email: firstname.lastname@example.org; SteadyMed: Marilyn Rigby, Senior Director, Investor Relations and Marketing, 925-272-4999, E-mail: email@example.com